Axcynsis Therapeutics is a pioneering biotechnology company headquartered in Singapore with operations in the United States. The company has developed AxcynDOT™ , a proprietary linker payload platform to advance a pipeline of differentiated ADC candidates aimed at addressing key unmet medical needs. The company is committed to advance effective and targeted oncology therapeutics with breakthrough potential to improve the lives of cancer patients worldwide.
